Advanced search
Publication Cover
Future Medicinal Chemistry Volume 14, 2022 - Issue 11
Submit an article Journal homepage
22
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Rapidly Evolving First-Line Therapy Using Checkpoint Inhibitors in Metastatic Renal Cell Cancer

Jeanny B Aragon-Ching1 GU Medical OncologyInova Schar Cancer InstituteFairfaxVA22031USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6714-141X
ORCID Icon
Pages 767-770 | Received 16 Oct 2021, Accepted 11 Apr 2022, Published online: 28 Apr 2022

References

  • Motzer RJ , EscudierB , McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
  • Motzer RJ , TannirNM , McDermottDFet al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med.378(14), 1277–1290 (2018).
  • Hegde PS , ChenDS. Top 10 challenges in cancer immunotherapy. Immunity52(1), 17–35 (2020).
  • Rini BI , SteinM , ShannonPet al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer117(4), 758–767 (2011).
  • Feldman DR , BaumMS , GinsbergMSet al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(9), 1432–1439 (2009).
  • Khetani VV , PortalDE , ShahMR , MayerT , SingerEA. Combination drug regimens for metastatic clear cell renal cell carcinoma. World J. Clin. Oncol.11(8), 541–562 (2020).
  • Rini BI , PowlesT , AtkinsMBet al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet393(10189), 2404–2415 (2019).
  • Rini BI , PlimackER , StusVet al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1116–1127 (2019).
  • Motzer RJ , PenkovK , HaanenJet al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1103–1115 (2019).
  • Choueiri TK , PowlesT , BurottoMet al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.384(9), 829–841 (2021).
  • Motzer R , AlekseevB , RhaSYet al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med.384(14), 1289–1300 (2021).
  • Albiges L , TannirNM , BurottoMet al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open5(6), e001079 (2020).
  • Choueiri TK , TomczakP , ParkSHet al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med.385(8), 683–694 (2021).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.